Abstract
: Pulmonary embolism is a life-threatening disease which represents with high mortality and morbidity. Systemic fibrinolysis is the first-line recommended therapy in hemodynamically instable patients with massive pulmonary embolism. Systemic fibrinolytic treatment remains controversial for pulmonary embolism after surgery due to high risk of hemorrhage. Herein, we report a 49-year-old man with massive pulmonary embolism after meniscus surgery, successfully treated with low-dose prolonged infusion of tissue type plasminogen activator.
MeSH terms
-
Anticoagulants / administration & dosage
-
Anticoagulants / therapeutic use
-
Fibrinolytic Agents / administration & dosage
-
Fibrinolytic Agents / therapeutic use*
-
Heparin / administration & dosage
-
Heparin / therapeutic use
-
Humans
-
Male
-
Meniscus / surgery*
-
Middle Aged
-
Orthopedic Procedures / adverse effects*
-
Pulmonary Embolism / blood
-
Pulmonary Embolism / drug therapy*
-
Pulmonary Embolism / etiology*
-
Pulmonary Embolism / pathology
-
Tissue Plasminogen Activator / administration & dosage
-
Tissue Plasminogen Activator / therapeutic use*
-
Warfarin / administration & dosage
-
Warfarin / therapeutic use
Substances
-
Anticoagulants
-
Fibrinolytic Agents
-
Warfarin
-
Heparin
-
Tissue Plasminogen Activator